Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Leukocyte adhesion deficiency type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Leukocyte adhesion deficiency type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Leukocyte adhesion deficiency type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Leukocyte adhesion deficiency type 1 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Leukocyte adhesion deficiency type 1 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Leukocyte adhesion deficiency type 1 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Mevalonic aciduria Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Mevalonic aciduria Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Mevalonic aciduria indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Purine nucleoside phosphorylase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Purine nucleoside phosphorylase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Purine nucleoside phosphorylase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →
Desmosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Desmosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Desmosterolosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Lathosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Lathosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Lathosterolosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Chylomicron retention disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Chylomicron retention disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Chylomicron retention disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Hypobetalipoproteinemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Hypobetalipoproteinemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Hypobetalipoproteinemia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Bile acid malabsorption Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Bile acid malabsorption Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Bile acid malabsorption strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Alagille syndrome cholestasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Alagille syndrome cholestasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Alagille syndrome cholestasis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Congenital bile acid synthesis defect Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital bile acid synthesis defect Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Congenital bile acid synthesis defect strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Congenital disorder of glycosylation type 1a Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital disorder of glycosylation type 1a Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Congenital disorder of glycosylation type 1a strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →